Двухнедельный обзор фондовых рынков №326. Между двух огней

Standard Motor Products, Inc. (SMP) is a prominent independent manufacturer and distributor of automotive aftermarket parts with a legacy spanning over 100 years. The acquisition of Nissens Automotive, finalized in late 2024, bolsters SMP’s position by merging its well-established North American operations with Nissens’ extensive European distribution network. The demand for auto repair services remains strong, as car owners are increasingly opting to maintain their existing vehicles rather than purchasing new ones. The average age of vehicle fleets in the U.S. and Europe has reached multi-year highs, and the total number of vehicles is on the rise, expanding the potential customer base for the service market. This geographic expansion, coupled with anticipated synergies from the Nissens integration, as well as aging vehicles and fleet growth, provides a solid foundation for SMP’s continued revenue and profitability growth. Freedom Broker analysts set a one-year price target of $42 for SMP shares.

Mueller Industries, Inc. (MLI) is a prominent manufacturer of copper, brass, aluminum, and plastic components in the U.S., with a significant presence in the piping, HVAC/R, and utility infrastructure segments. Despite structural challenges in the residential construction industry, MLI’s earnings sustainability is ensured by efficient operations, disciplined cost management, and an increasing focus on government-supported markets. Margin expansion, consistent cash flow generation, and a net cash position enable MLI to outperform its peers throughout the economic cycle. This also permits the company to execute selective M&As, enhancing vertical integration and market diversification. In Q2 2025, Mueller Industries released record results, showcasing its resilience despite weaknesses in the construction sector. Freedom Broker analysts set a one-year price target of $99 for MLI shares.

Cooper-Standard Holdings Inc. (CPS), a prominent U.S. manufacturer of automotive components, is recognized as the world’s leading supplier of automotive door sealing systems and ranks as the second-largest supplier of automotive fuel and brake fluid systems. Over the past three years, more than 50% of Cooper-Standard’s revenue has been derived from the three largest U.S. automakers—Ford, General Motors, and Stellantis. This concentration offers order stability and revenue predictability over the auto lifecycle; however, it also highlights potential risks associated with revenue concentration. Despite a decline in revenue during Q1 2025, the company has successfully increased its operating income and is actively working to reduce its leverage. These efforts are anticipated to positively influence net income and interest coverage. Management is placing an emphasis on the Chinese market, projecting that up to 80% of sales will originate from Chinese automakers by 2027. While we hold a less optimistic outlook on the company’s growth prospects in China, accelerated sales in this region may indeed bolster overall revenue growth beyond 2025. Freedom Broker analysts set a one-year price target of $33 for CPS shares.

Atara Biotherapeutics, Inc. (ATRA) is an American biotechnology company that focuses on the development of allogeneic T-cell immunotherapies. Atara, in collaboration with its partner Pierre Fabre, has resubmitted the application for the approval of Tab-cel, an investigational drug intended to treat a rare form of Epstein-Barr virus-related cancer (EBV+ PTLD). This application has been granted priority review status, and a decision date is set for January 10, 2026, precisely one year after the previous attempt, which was unsuccessful due to manufacturing issues. This marks a pivotal milestone for Atara, as the company’s current financial resources are only enough until the first quarter of 2026. Should approval be granted, it would not only secure $40 million from the partner but also prolong the company’s financial stability. We assign a high probability of a favourable decision, given that the FDA’s previous concerns were limited to manufacturing processes and did not address the drug’s efficacy or safety. Freedom Broker analysts set a one-year price target of $16 for ATRA shares.